Physician profile
Marcus Sandling
NPI 1396001418
$156,791.88
in general payments reported to CMS, 2019-2025
6 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $5,486 · 2023: $641 · 2024: $68K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Consulting Fee: $22K · Travel and Lodging: $19K · Food and Beverage: $5,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,815.00 |
| Consulting Fee | $22,380.00 |
| Travel and Lodging | $18,880.26 |
| Food and Beverage | $5,778.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $112,426.98 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $43,249.45 | 2019-2025 | Yeztugo, Descovy, Biktarvy |
| Bavarian Nordic A/S | $750.00 | 2025 | Jynneos |
| Janssen Biotech, INC. | $171.46 | 2019-2020 | |
| Janssen Products, LP | $121.11 | 2020 | |
| Merck Sharp & Dohme LLC | $72.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Sandling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.